受终端需求回暖及客户订单交付节奏影响，报告期内公司交付订单增加;同时受交付订单产品结构影 响，公司总体毛利率有所提高。 智通财经APP讯，金凯生科(301509.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 9200万元至1.16亿元，同比增长138.28%至200.45%;扣除非经常性损益后的净利润7200万元至9100万 元，同比增长314.69%至424.12%。 ...

金凯生科(301509.SZ)发布2025年度业绩预告，预计归属于上市公司股东的净利润为9200万元–1.16亿 元，比上年同期增长138.28%–200.45%。受终端需求回暖及客户订单交付节奏影响，报告期内公司交付 订单增加；同时受交付订单产品结构影响，公司总体毛利率有所提高。以上综合因素导致公司2025年度 业绩同比出现较大幅度提升。 ...

（文章来源：每日经济新闻） 每经AI快讯，金凯生科(301509)1月23日发布业绩预告，预计2025年归母净利9200万元~1.16亿元，同比 增长138.28%~200.45%。受终端需求回暖及客户订单交付节奏影响，报告期内公司交付订单增加；同时 受交付订单产品结构影响，公司总体毛利率有所提高。 ...

证券代码：301509 证券简称：金凯生科 公告编号：2026-001 金凯（辽宁）生命科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算结果，未经注册会计师预审 计。公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与 会计师事务所在本次业绩预告方面不存在分歧。 三、业绩变动原因说明 受终端需求回暖及客户订单交付节奏影响，报告期内公司交付订单增加；同 时受交付订单产品结构影响，公司总体毛利率有所提高。以上综合因素导致公司 2025 年度业绩同比出现较大幅度提升。 四、其他相关说明 本次业绩预告数据是公司财务部门初步测算的结果，具体财务数据将在公司 2025 年年度报告中详细披露，敬请广大投资者理性投资，注意风险。 1 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形。 单位：万元 | 项 | 目 | 本报告期 | ...

（文章来源：证券日报） 证券日报网讯 1月21日，金凯生科在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东 数为14722户。 ...

（文章来源：证券日报） 证券日报网讯 1月13日，金凯生科在互动平台回答投资者提问时表示，截至2026年1月9日，公司股东数 为14538户。 ...

Core Viewpoint - The company JinKai Life Science has shown significant growth in revenue and profit, driven by its CDMO services for pharmaceutical companies and benefiting from the depreciation of the RMB [4][8]. Group 1: Company Overview - JinKai Life Science Co., Ltd. is located in Fuxin City, Liaoning Province, and was established on June 8, 2009, with its IPO on August 3, 2023 [8]. - The company specializes in providing custom development and manufacturing services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies [2][8]. - The main revenue sources include 98.36% from product sales, 0.90% from technical services, 0.67% from trade services, and 0.07% from other sources [8]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96% [8]. - The net profit attributable to the parent company was 103 million yuan, showing a remarkable year-on-year increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Position and Trends - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 61.18% of total revenue [4]. - The company is involved in various concepts including CRO, weight loss drugs, Alzheimer's-related services, and fluorochemical products [2][3]. - The stock has seen a recent increase in trading volume and interest, with a significant net inflow of 8.75 million yuan on the latest trading day [5][6].

Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the six-month moving average, with a change of -0.03% [1] - The total trading volume of A-shares today is 185.05 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 168 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Nearshore Protein (近岸蛋白) with a deviation rate of 19.69% and a price increase of 19.99% [1] - Erkang Pharmaceutical (尔康制药) with a deviation rate of 17.97% and a price increase of 19.14% [1] - Wanbang Pharmaceutical (万邦医药) with a deviation rate of 12.41% and a price increase of 12.85% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Bo Wen Technology (博闻科技) with a deviation rate just above the average [1] - Jilin Expressway (吉林高速) and Teda Investment (泰达股份) also show minor deviations [1] Additional Notable Stocks - Other stocks with notable performance include: - Deer Medical (鹿得医疗) with a price increase of 13.63% and a deviation rate of 11.86% [1] - Chuaning Biological (川宁生物) with a price increase of 12.84% and a deviation rate of 10.67% [1] - New Zhi Biological (新芝生物) with a price increase of 14.33% and a deviation rate of 10.66% [1]

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main business involves offering small molecule CDMO services to global life science clients, assisting in the synthesis process of innovative drug development [8]. - The company's revenue composition includes 98.36% from product sales, 0.90% from technical services, 0.67% from trade services, and 0.07% from other sources [8]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to the parent company of 103 million yuan, reflecting a significant increase of 163.24% [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Market Position - As of December 19, the number of shareholders in the company was 14,300, a decrease of 0.54% from the previous period, while the average circulating shares per person increased by 0.54% to 3,974 shares [8]. - The company benefits from a 61.18% overseas revenue share, aided by the depreciation of the Chinese yuan [4]. Product and Service Development - The company is involved in the development of intermediates for drugs related to Alzheimer's disease and has capabilities in producing specialized fluorinated agents [3][4]. - The company’s listed fundraising projects include the "Pharmaceutical Intermediate Project" and a project for producing 190 tons of high-end pharmaceutical products, which includes intermediates for Semaglutide oral formulations [2][3].

证券日报网讯1月6日，金凯生科（301509）在互动平台回答投资者提问时表示，截至2025年12月31日， 公司股东数为14132户。 ...